Overview

Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Study to assess safety, tolerability and pharmacokinetics of BIRB 1017 BS in single rising oral doses of 5 to 800 mg in a polyethylene glycol 400 (PEG 400) / 26% ethanol solution in healthy male subjects

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Ethanol